NCT04664309

Brief Summary

The purpose of this study is to test over time immunity to the COVID-19 vaccines. Adults who are receiving COVID-19 vaccines will be invited to participate.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
43

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Mar 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 9, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 11, 2020

Completed
4 months until next milestone

Study Start

First participant enrolled

March 26, 2021

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 6, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 6, 2022

Completed
Last Updated

February 28, 2022

Status Verified

February 1, 2022

Enrollment Period

10 months

First QC Date

December 9, 2020

Last Update Submit

February 9, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Percentage of participants with immunity to COVID-19 vaccines over time

    1 year

Study Arms (1)

Participants

Adults who are receiving a COVID-19 vaccine

Other: No intervention

Interventions

No intervention

Participants

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults (18 years and older) receiving a COVID-19 vaccine

You may qualify if:

  • Adults who are receiving a COVID-19 vaccine

You may not qualify if:

  • Patients with special risks attendant to venipuncture

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford University, Hospital, and Clinics

Stanford, California, 94305, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Blood samples, saliva, nasal swabs

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Kari Nadeau, MD, PhD

    Stanford University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Medicine

Study Record Dates

First Submitted

December 9, 2020

First Posted

December 11, 2020

Study Start

March 26, 2021

Primary Completion

January 6, 2022

Study Completion

January 6, 2022

Last Updated

February 28, 2022

Record last verified: 2022-02

Data Sharing

IPD Sharing
Will not share

Locations